Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-15 · accession 0001177648-21-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-17 | 2021-09-15 | ENTA | Luly Jay R. | Pres, CEO, Dir | S - Sale | $59.06 | -4,516 | 677.0K | -0.7% | -$266.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-15 | S | D | 4,516 | $59.06 | 676,972 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.23, inclusive. |